Insulin Or Derivative Utilizing Patents (Class 514/5.9)
-
Publication number: 20140162947Abstract: The use of Kruppel-like Factor (KLF10) as a diagnostic and prognostic tool for peripheral artery disease and other disease conditions associated with reduced angiogenesis or endothelial progenitor cell dysfunction such as diabetes and stent thrombosis.Type: ApplicationFiled: March 9, 2012Publication date: June 12, 2014Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Mark W. Feinberg, Akm Khyrul Wara
-
Patent number: 8741260Abstract: The invention provides compositions, methods, and kits for increasing transport of GDNF across the blood brain barrier while allowing its activity to remain substantially intact. The GDNF is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems.Type: GrantFiled: November 25, 2008Date of Patent: June 3, 2014Assignee: Armagen Technologies, Inc.Inventors: William M. Pardridge, Ruben J. Boado
-
Patent number: 8734831Abstract: A method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid coating layer containing a bioactive factor includes (a) forming a porous ceramic scaffold; (b) mixing a silica xerogel and a physiologically active organic substance in a volumetric ratio ranging from 30:70 to 90:10 and treating by a sol gel method to prepare an organic/inorganic hybrid composite solution; (c) adding a bioactive factor to the organic/inorganic hybrid composite solution and agitating until gelation occurs; and (d) coating the porous ceramic scaffold with the organic/inorganic composite containing the bioactive factor added thereto. In accordance with the method, the porous ceramic scaffold may be uniformly coated with the organic/inorganic hybrid composite while maintaining an open pore structure, and stably discharge the bioactive factor over a long period of time.Type: GrantFiled: April 15, 2011Date of Patent: May 27, 2014Assignee: SNU R&DB FoundationInventors: Hyoun-Ee Kim, Shin-Hee Jun, Eun-Jung Lee
-
Publication number: 20140142034Abstract: The invention relates to a composition in aqueous solution, including insulin and at least one substituted anionic compound chosen from substituted anionic compounds consisting of a backbone formed from a discrete number u of between 1 and 8 (1?u?8) of identical or different saccharide units, linked via identical or different glycoside bonds, said saccharide units being chosen from the group consisting of hexoses, in cyclic form or in open reduced form, said compound comprising partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. The invention also relates to a pharmaceutical formulation comprising a composition as claimed in any one of the preceding claims.Type: ApplicationFiled: November 13, 2013Publication date: May 22, 2014Inventors: Olivier SOULA, Gérard SOULA, Emmanuel DAUTY
-
Patent number: 8728525Abstract: The present disclosure relates to compositions of methods of making and compositions small compositions of particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in a single liquid phase. The solution is subjected to a liquid-solid phase separation to cause the active agent to form small spherical particles that are substantially amorphous or non-crystalline and are injectable through fine bore needles at high concentrations. The particles exhibit the pharmacokinetic and pharmacodynamnic properties of the active agent. The disclosure has special application for higher molecular weight proteins such as antibodies.Type: GrantFiled: November 7, 2006Date of Patent: May 20, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Larry R. Brown, Mark X. Yang, Ed O'Connell
-
Patent number: 8728491Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.Type: GrantFiled: May 7, 2008Date of Patent: May 20, 2014Assignee: Alba Therapeutics CorporationInventors: Dorothea Sesardic, Blake Paterson
-
Patent number: 8729019Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties.Type: GrantFiled: July 6, 2010Date of Patent: May 20, 2014Assignee: Mannkind CorporationInventors: Keith A. Oberg, Joseph Sulner
-
Patent number: 8729016Abstract: Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing ?-cell function, aiding in preventing ?-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration.Type: GrantFiled: June 16, 2009Date of Patent: May 20, 2014Assignee: Emisphere Technologies, Inc.Inventors: Ehud Arbit, Michael Goldberg, Shingai Majuru
-
Patent number: 8728813Abstract: A method of ex-vivo increasing insulin content in progenitor cells which express SLUG is provided. The method comprises downregulating an amount or activity of SLUG in the progenitor cells. Cell populations generated thereby and uses thereof are also provided.Type: GrantFiled: December 28, 2011Date of Patent: May 20, 2014Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Shimon Efrat, Yael Bar, Holger A. Russ
-
Publication number: 20140135263Abstract: Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection. In the preferred embodiment, the insulin is provided as a dry powder in a sterile vial. This is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water, a zinc chelator such as EDTA and a dissolution agent such as citric acid shortly before or at the time of administration.Type: ApplicationFiled: January 15, 2014Publication date: May 15, 2014Applicant: Biodel Inc.Inventors: Roderike Pohl, Solomon S. Steiner
-
Patent number: 8722620Abstract: The present invention is related to insulin derivatives having a side chain attached to an ?-amino group of a Lys residue present in the A-chain or to an ?-amino group of a Lys residue in the B-chain.Type: GrantFiled: February 27, 2007Date of Patent: May 13, 2014Assignee: Novo Nordisk A/SInventors: Charlotte Harkjaer Fynbo, Ib Jonassen, Thomas Børglum Kjeldsen, Peter Madsen, Patrick William Garibay, Janos Tibor Kodra, Thomas Hoeg-Jensen, Tina Møller Tagmose
-
Patent number: 8716221Abstract: The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity to SEQ ID No. 17 and the amino acid sequence has a higher stability than the non-modified exendin of SEQ ID No. 4. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.Type: GrantFiled: December 22, 2011Date of Patent: May 6, 2014Assignee: Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.Inventors: Aifeng Lv, Changan Sun, Yali Wang
-
Publication number: 20140120161Abstract: A vector for the oral administration of at least one pharmacologically active substance enabling the active substance to move from the intestinal lumen to the blood, optionally via interstitial liquid, without any substantial degradation of the substance, includes an essentially hydrophilic matrix having an outer surface which is modified by one or several chemical species providing the vector with an essentially lipophilic quality and containing one or several active substances. The vector is associated with a gastroresistant vehicle enabling it to pass into the stomach without any denaturation and/or degradation of the active substance. The invention also relates to pharmaceutical compositions containing the vector. The vectors can be used to produce medicaments used in human or veterinary medicine.Type: ApplicationFiled: December 24, 2013Publication date: May 1, 2014Applicants: CENTRE EUROPEEN D'ETUDE DU DIABETE (30% PARTIAL INTEREST), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: YVES FRERE, LOUIS DANICHER, ALAIN BELCOURT
-
Publication number: 20140121159Abstract: The present disclosure provides inter alia conjugates of formula (I): wherein n, R1, R2, Rx, Z, X, Y and Z are as defined herein. A conjugate of formula (I) can also be converted to a conjugate of formulae (II) or (III) as described herein. Without limitation, the conjugates can be used to make controlled release materials and chemical sensors.Type: ApplicationFiled: December 3, 2013Publication date: May 1, 2014Applicant: SmartCells, Inc.Inventors: Todd C. Zion, Thomas M. Lancaster
-
METHODS AND SYSTEMS FOR MEASURING AND USING THE OXIDATION-REDUCTION POTENTIAL OF A BIOLOGICAL SAMPLE
Publication number: 20140121158Abstract: Methods and systems for measuring and using the oxidation-reduction characteristics of a biological sample are provided. The system generally includes a test strip and a readout device. A fluid sample is placed in the test strip, and the test strip is in turn operatively connected to the readout device. The readout device provides a controlled current that is sent across the fluid in the sample chamber. In addition, the readout device identifies an inflection point or transition time at which the voltage between contacts of the test strip is changing at the highest rate. The oxidation-reduction capacity of the sample is taken as the integral of the current profile from the time at which current begins to be supplied to the sample to the identified transition time.Type: ApplicationFiled: October 23, 2013Publication date: May 1, 2014Applicant: Luoxis Diagnostics, Inc.Inventors: Raphael Bar-Or, David Bar-Or, Leonard T. Rael -
Patent number: 8710000Abstract: The present invention relates to novel human insulin derivatives which are soluble at physiological pH values and have a prolonged profile of action. The invention also relates to pharmaceutical compositions containing such derivatives and to methods of treating diabetes and hyperglycaemia using the insulin derivatives of the invention.Type: GrantFiled: November 7, 2008Date of Patent: April 29, 2014Assignee: Novo Nordisk A/SInventors: Patrick William Garibay, Thomas Høeg-Jensen
-
Patent number: 8710001Abstract: PEGylated, extended insulins are insulins which, compared with human insulin, has one or more extensions extended from the A1, B1, A21 and/or B30 position(s), said extension(s) consist(s) of amino acid residue(s) and wherein a PEG moiety, via a linker, is attached to one or more of the amino acid residues in the extension(s). PEG is polyethyleneglycol. Such PEGylated, extended insulins have higher bioavailability and a longer time-action profile than regular insulin and are in particular suited for pulmonary administration and can, conveniently, be used to treat diabetes.Type: GrantFiled: September 2, 2011Date of Patent: April 29, 2014Assignee: Novo Nordisk A/SInventors: Peter Madsen, Thomas Børglum Kjeldsen, Tina Møller Tagmose, Palle Jakobsen
-
Publication number: 20140107023Abstract: The present invention relates to a non-peptidyl polymer-insulin multimer comprising two or more of a non-peptidyl polymer-insulin conjugate prepared by linking a non-peptidyl polymer and insulin via a covalent bond, in which the conjugates are complexed with cobalt ion to form a multimer, a method and kit for the preparation of the multimer, a pharmaceutical composition for the prevention or treatment of diabetes comprising the multimer as an active ingredient, and a method for preventing or treating diabetes by administering the composition to a subject.Type: ApplicationFiled: June 1, 2012Publication date: April 17, 2014Applicant: HANMI SCIENCE CO., LTDInventors: Sung In Lim, Myung Hyun Jang, Dae Jin Kim, Sung Youb Jung, Se Chang Kwon
-
Publication number: 20140105993Abstract: The present invention relates to novel microparticles formed of amphiphilic polyamino acids which transport active principle(s), AP(s), in particular protein and peptide active principle(s), and to novel modified-release pharmaceutical formulations comprising said AP microparticles. Microparticles of amphiphilic polyamino acid (PO) may include at least one AP (associated noncovalently) which spontaneously form a colloidal suspension of nanoparticles in water, at pH 7.0, under isotonic conditions. The microparticles may be obtained by atomization of a solution or colloidal suspension of PO comprising at least one AP, may have a size of between 0.5 and 100 microns, and may be dispersible in colloidal suspension.Type: ApplicationFiled: November 21, 2013Publication date: April 17, 2014Applicant: Flamel Technologies, S.A.Inventors: Alain Constancis, You-Ping Chan
-
Publication number: 20140105857Abstract: Compositions and methods for enhancing the absorption of active agents across the mucosa of animal subjects are provided. Methods of administration and appropriate dosage forms are also provided.Type: ApplicationFiled: March 14, 2013Publication date: April 17, 2014Applicant: Nexus Pharma, Inc.Inventor: Chung Shih
-
Patent number: 8697838Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.Type: GrantFiled: July 28, 2010Date of Patent: April 15, 2014Assignee: Indiana University Research and Technology CorporationInventors: Richard D. Dimarchi, Arnab De
-
Patent number: 8697644Abstract: Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations.Type: GrantFiled: March 9, 2012Date of Patent: April 15, 2014Assignee: Xeris Pharmaceuticals, Inc.Inventors: Steven Prestrelski, John Kinzell
-
Patent number: 8697643Abstract: A conjugate that includes a drug covalently linked to a polymer. Upon administration, the conjugate is digested by an enzyme that is present at the site of administration thereby releasing a therapeutic agent. The conjugate may demonstrate substantially the same pharmacokinetic and pharmacodynamic behavior as the drug itself. A material for controllably releasing a conjugate in response to the local concentration of a molecular indicator. The material includes a plurality of conjugates and a plurality of multivalent cross-linking agents. The polymers of the conjugates include an analog of the indicator within their covalent structure. The multivalent cross-linking agents include cross-link receptors that interact with the indicator analog and thereby cross-link the conjugates.Type: GrantFiled: February 6, 2012Date of Patent: April 15, 2014Assignee: SmartCells, Inc.Inventors: Thomas M. Lancaster, Matthew Nalewanski, Todd C. Zion
-
Publication number: 20140100158Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.Type: ApplicationFiled: December 10, 2013Publication date: April 10, 2014Applicant: MannKind CorporationInventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
-
Patent number: 8691759Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.Type: GrantFiled: March 13, 2009Date of Patent: April 8, 2014Assignee: Novo Nordisk A/SInventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Janos Tibor Kodra, Patrick William Garibay
-
Patent number: 8691268Abstract: A method for delivery of substance through at least one dermal layer, by providing a substance in microcapsules at a predetermined size, within a medium (150) for holding the microcapsules; placing the medium for holding the microcapsules on a surface of a patch (100) adjacent the skin (320) of a human or animal; and applying energy (200) to the patch, the energy having a characteristic of disturbing the integrity of the microcapsules, thereby resulting in release of the substance from the microcapsules. The energy may be selectively applied to release the substance at desired times. The substance may be a drug or other active agent.Type: GrantFiled: September 15, 2010Date of Patent: April 8, 2014Assignee: Ultra-Sonic Technologies, L.L.C.Inventor: Ludwig J. Weimann
-
Patent number: 8685934Abstract: The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided.Type: GrantFiled: May 26, 2010Date of Patent: April 1, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Paul Strumph, Stephanie Moran, James List
-
Publication number: 20140086994Abstract: The invention provides an apparatus for forming fine particles of a substance in a precipitation chamber, in which the apparatus has means to convey the fine particles from the precipitation chamber to at least one particle collection chamber, downstream of the precipitation chamber, the particle collection chamber having an inlet and an outlet separate from the inlet. The invention also provides a method of forming fine particles of a substance, the method comprising contacting a non-gaseous fluid containing the substance with a dense fluid to expand the non-gaseous fluid in a precipitation chamber, conveying a resulting mixture of fluid and the fine particles from the precipitation chamber to a collection chamber, the collection chamber having an inlet and an outlet separate from the inlet.Type: ApplicationFiled: December 4, 2013Publication date: March 27, 2014Applicant: MAP Pharmaceuticals, Inc.Inventors: Neil Russell Foster, Hubert Leonardus Regtop, Fariba Dehghani
-
Publication number: 20140088001Abstract: The present application pertains to a technique useful for the differentiation and diagnosis of organ specificity of hyperglycemia and glucose intolerance in type 2 diabetes, pre-diabetes or populations with risk to develop type 2 diabetes.Type: ApplicationFiled: March 11, 2013Publication date: March 27, 2014Applicant: Mayo Foundation for Medical Education and ResearchInventor: Mayo Foundation for Medical Education and Research
-
Publication number: 20140079782Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.Type: ApplicationFiled: September 18, 2012Publication date: March 20, 2014Applicant: NEKTAR THERAPEUTICSInventors: PETER YORK, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
-
Publication number: 20140072531Abstract: A method for preparing polymer microparticles with a reduced initial burst, and the polymer microparticles prepared thereby, the method including: contacting polymer microparticles with an alcohol aqueous solution, the polymer microparticles prepared thereby, and use for drug delivery of the polymer microparticles.Type: ApplicationFiled: November 20, 2013Publication date: March 13, 2014Applicant: SK CHEMICALS CO., LTD.Inventors: Hong Kee KIM, Kyu Ho Lee, Joon-Gyo OH, Bong-Yong Lee
-
Publication number: 20140072588Abstract: Absorption of a therapeutic agent across a mucosal membrane or the skin can be enhanced using an absorption enhancer comprising a hydroxy fatty acid ester of polyethylene glycol.Type: ApplicationFiled: November 14, 2013Publication date: March 13, 2014Applicant: Critical Pharmaceuticals LimitedInventors: Lisbeth Illum, Faron Michael Jordan, Andrew Lester Lewis
-
Publication number: 20140073564Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.Type: ApplicationFiled: August 22, 2013Publication date: March 13, 2014Applicant: Novo Nordisk A/SInventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Jaanos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
-
Patent number: 8669227Abstract: The invention relates to a complex between an insulin and a polysaccharide comprising carboxyl functional groups, said polysaccharide being chosen from polysaccharides functionalized with at least one phenylalanine derivative, noted Phe, said phenylalanine derivative being chosen from the group consisting of phenylalanine and its alkali metal cation salts, phenylalaninol, phenylalaninamide and ethylbenzylamine or from phenylalanine esters, and said insulin being either a human insulin or an insulin analog. The invention also relates to a pharmaceutical composition comprising at least one complex according to the invention, especially in the form of an injectable solution.Type: GrantFiled: March 29, 2010Date of Patent: March 11, 2014Assignee: AdociaInventors: Olivier Soula, Remi Soula, Gerard Soula
-
Publication number: 20140056953Abstract: The present invention relates to fatty acid acylated amino acids (FA-aa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such FA-aa's.Type: ApplicationFiled: April 12, 2012Publication date: February 27, 2014Applicant: NOVO NORDISK A/SInventors: Florian Anders Foeger, Abdallah Makhlof, Herbert Hoyer
-
Publication number: 20140052051Abstract: Disclosed are a patch, system, and method for delivery of a permeant composition into a subject via at least one formed pathway through a biological membrane of the subject. The patch comprises a matrix, at least one hydrophilic permeant disposed within the matrix, wherein at least a portion of the permeant can dissolve in biological moisture received from the subject, and at least one permeability enhancer disposed within the matrix. Also disclosed are systems and methods for delivery of a permeant composition into a subject via at least one formed pathway through a skin layer of the subject.Type: ApplicationFiled: October 28, 2013Publication date: February 20, 2014Applicant: NITTO DENKO CORPORATIONInventors: FRANK TAGLIAFERRI, ALAN SMITH, DAVID ENSCORE, GAURAV TOLIA, MIREK BAUDYS
-
Publication number: 20140051628Abstract: The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (ZyHisw)p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.Type: ApplicationFiled: July 26, 2013Publication date: February 20, 2014Applicant: Pharmaln CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin
-
Publication number: 20140045745Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.Type: ApplicationFiled: September 3, 2013Publication date: February 13, 2014Applicant: MannKind CorporationInventors: Marshall L. Grant, Grayson W. Stowell, Paul Menkin
-
Publication number: 20140044790Abstract: Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.Type: ApplicationFiled: October 29, 2013Publication date: February 13, 2014Applicant: MannKind CorporationInventors: Edwin Amoro, Karel Vanackere, Michael A. White
-
Publication number: 20140037743Abstract: The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa.Type: ApplicationFiled: October 11, 2013Publication date: February 6, 2014Applicant: DelivRx, Inc.Inventor: Daniel R. DeBrouse
-
Publication number: 20140031280Abstract: Methods for preventing and/or treating symptoms of Post-Traumatic Stress Disorder (PTSD) are provided. The preferred method comprises administration of an effective amount of insulin to the upper one-third of a mammal's, preferably a human, nasal cavity, thereby enabling the administered at least one effective amount of insulin to bypass the patient's blood-brain barrier and be directly delivered to the patient's CNS. Another embodiment comprises utilizing vasoconstrictors to enhance targeting of an effective amount of insulin to the CNS while reducing non-target exposure.Type: ApplicationFiled: September 30, 2013Publication date: January 30, 2014Applicant: HealthPartners Research & EducationInventor: William H. Frey, II
-
Patent number: 8637458Abstract: A basal insulin formulation composed of insulin, preferably insulin glargine, injectable zinc and injectable iron compounds as precipitating and/or stabilizing agents has been developed for subcutaneous, intradermal or intramuscular administration. The formulation is designed to form a precipitate of insulin following injection, creating a slow releasing “basal insulin” over a period of 12 to 24 hours.Type: GrantFiled: May 12, 2010Date of Patent: January 28, 2014Assignee: Biodel Inc.Inventors: Roderike Pohl, Nandini Kashyap, Robert Hauser, Koray Ozhan, Solomon S. Steiner
-
Publication number: 20140023615Abstract: The present invention provides thermo-sensitive, mucoadhesive biopolymer formulations that enhance the penetration of therapeutics across the skin or mucosal surfaces. In a preferred embodiment, the biopolymer formulation comprises co-polymer of poloxamer 188 and propylene glycol, laurocapram and, optionally, one or more therapeutic agents. Also provided are uses of the biopolymer formulations for topical therapy of cancer including cervical cancer.Type: ApplicationFiled: March 29, 2012Publication date: January 23, 2014Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventor: Stephen I-Hong Hsu
-
Publication number: 20140024582Abstract: The invention provides methods for improving the physical and chemical stabilities of therapeutic proteins in solutions by reducing or eliminating protein degradation, aggregation and precipitation using small molecule stabilizing agents such as proline, arginine and/or compounds capable of forming a Schiff bond with amino groups of the protein. The invention further provides liquid formulations of a monomeric insulin stabilized by one of more stabilizing agents such as proline, arginine and/or acetone. Also provided are methods of making and using the stabilized monomeric insulin formulations.Type: ApplicationFiled: March 21, 2013Publication date: January 23, 2014Applicant: GENECOPOEIA, INC.Inventor: Guohan YANG
-
Patent number: 8633156Abstract: The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the addition and/or substitution of negatively and positively charged amino acid residues and by an amidation of the C-terminal carboxy group of the B chain and histidine in position 8 of the insulin A chain. The invention also relates to the production and use thereof.Type: GrantFiled: June 22, 2010Date of Patent: January 21, 2014Assignee: Sanofi-Aventis Deutschland GmbHInventors: Paul Habermann, Gerhard Seipke, Roland Kurrle, Gunter Muller, Mark Sommerfeld, Norbert Tennagels, Georg Tschank, Ulrich Werner
-
Patent number: 8632803Abstract: A pharmaceutical composition containing a therapeutic protein which is particularly amenable to oral administration by providing stability in the gastrointestinal tract. Insoluble fibrils or aggregates of the therapeutic protein in the pharmaceutical composition are encapsulated in a lipidated glycosaminoglycan particle, coated with a multi-layer of lipids and lipid-glycosaminoglycan conjugates, or present as unencapsulated and uncoated insoluble fibrils or aggregates.Type: GrantFiled: February 18, 2009Date of Patent: January 21, 2014Assignee: Ramot At Tel-Aviv University Ltd.Inventors: Yaron Dekel, Rimona Margalit
-
Publication number: 20140017331Abstract: The invention relates to new amphiphilic linear block copolymers of polysaccharides and polymers. The amphiphilic linear block copolymers do not form a true solution in water and are able to form micelles in selective solvents. Also disclosed are particles, each of which has a shell and a core, and a diameter of about 1 to 1,000 nanometers, and methods of delivering agents or removing substances, e.g., undesirable substances, from a subject or environment, by using these particles.Type: ApplicationFiled: September 12, 2013Publication date: January 16, 2014Inventors: Stephen J. McCarthy, Balint Koroskenyi, Robert J. Nicolosi
-
Publication number: 20140011739Abstract: The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such as Giardia sp. variable surface proteins (VSP), to deliver therapeutic agents. VSP drug carriers can be combined with bioactive peptides, e.g., insulin, glucagon, or hGH, and be administered orally or mucosally. VSP carriers are resistant to acidic pHs and to proteolytic degradation and protect therapeutic agents from degradation in the gastrointestinal tract.Type: ApplicationFiled: March 15, 2013Publication date: January 9, 2014Inventors: David KLATZMANN, Eliane Piaggio, Hugo Lujan
-
Publication number: 20140007873Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.Type: ApplicationFiled: June 18, 2013Publication date: January 9, 2014Applicant: MannKind CorporationInventors: Chad C. Smutney, P. Spencer Kinsey, Carl R. Sahi, Benoit Adamo, John M. Polidoro, Scott McLean, Dennis Overfield, Kelly S. Kraft, Karla Somerville
-
Patent number: 8623817Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.Type: GrantFiled: January 17, 2012Date of Patent: January 7, 2014Assignee: Mannkind CorporationInventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci